# US 2024/0197681 A1 · Methods and compositions relating to psychedelics and serotonin receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197681 A1
- Document ID: US20240197681A1
- Status: Published application
- Kind: A1
- Application number: 18/553,170
- Filed: 2022-04-01
- Published: 2024-06-20
- Earliest claimed: 2021-04-01
- Assignees: Terran Biosciences Inc.; University of Maryland, Baltimore
- Applicants: Terran Biosciences Inc.; University of Maryland, Baltimore
- Inventors: Sam CLARK; Scott THOMPSON
- Web page: https://patentgrep.com/patent/US20240197681A1

## CPC

- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/24: Antidepressants
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions relating to psychedelics and serotonin receptor modulators. Further provided herein are methods of treating a disease or disorder (e.g., depression or diseases or disorders related to depression) comprising administering psychedelics and serotonin receptor modulators.

## Claims

### Claim 1

A composition comprising:
a) a psychedelic;
b) a serotonin receptor modulator; and
c) an excipient,
wherein the serotonin receptor modulator is released at most about 3 hours prior to the release of the psychedelic.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the psychedelic is an agonist for a serotonin receptor.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the serotonin receptor is serotonin receptor 1B, serotonin receptor 4, serotonin receptor 6, or serotonin receptor 7.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the psychedelic is selected from psilocybin, psilocin, baeocystin, norbaeocystin, lisurgide, LSD, dimethyltryptamine, carboxamindotryptamine, ibogaine, tabernanthalog, 3,4-methylenedioxy-methamphetamine (MDMA), 1-acetyl LSD, O-acetyl psilocin, mescaline (3,4,5-trimethoxy phenethylamine), proscaline (2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine), metaescaline (2-(3-ethoxy-4,5-dimethoxyphenyl)ethanamine), allylescaline (4-Allyloxy-3,5-dimethyloxy phenylethylamine), methallylescaline (4-Methallyloxy-3,5 dimethoxyphenethylamine), and asymbescaline (3,4-Diethoxy-5-methoxyphenethylamine), or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, prodrug, or combinations thereof.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the psychedelic is LSD or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the LSD derivative is 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, LSZ, LSM-775, or 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the psychedelic is mescaline or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the mescaline derivative is mescaline-NBOMe, proscaline (2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine), or metaescaline (2-(3-ethoxy-4,5-dimethoxyphenyl)ethanamine).

### Claim 9 (depends on 1)

The composition of claim 1, wherein the psychedelic is a phenethylamine or a tryptamine, or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the phenethylamine or the tryptaminedeuterated analogue is selected from the group consisting of 25I-NBOH, N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-iodo-phenethylamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-chloro-phenethylamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-bromo-phenethylamine, 4-Allyloxy-3,5-dimethyloxyphenylethylamine, N-(2-fluorobenzyl)-2,5-dimethoxy-4-iodo-phenethylamine, 2,5-dimethoxy-4-tert-butylthio-phenethylamine, 2,5-dimethoxy-4-propylthio-phenethylamine, 2,5-dimethoxy-4-propylphenethylamine, 2,5-dimethoxy-4-nitrophenethylamine, 2,5-dimethoxy-4-nitroamphetamine, 2,5-dimethoxy-4-methylphenethylamine, 2,5-dimethoxy-4-methylamphetamine, 2,5-dimethoxy-4-isopropylthio-phenethylamine, 2,5-dimethoxy-4-iodophenethylamine, 2,5-dimethoxy-4-iodoamphetamine, 2,5-dimethoxy-4-fluorophenethylamine, 2,5-dimethoxy-4-ethylthio-phenethylamine, 2,5-dimethoxy-4-ethylphenethylamine, 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine, 2,5-dimethoxy-4-chlorophenethylamine, 2,5-dimethoxy-4-chloroamphetamine, 2,5-dimethoxy-4-bromophenethylamine, 2,5-dimethoxy-4-bromoamphetamine, 2,5-dimethoxy-4-bromo-ß-ketophenethylamine, 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine, 2-(4-propyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-methyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-fluoro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 4-AcO-MET, 4-AcO-MALT, 4-AcO-DALT, Aeruginascin, N,N,N-trimethyl-4-phosphoryloxytryptamine, 4-Hydroxy-N,N,N-trimethyltryptamine, 5-meo-DMT, Ibogaine, [3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, 4-hydroxy-N,N-dimethyl-tryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N,N-trimethyltryptamine, 6-Allyl-N,N-diethyl-NL, N,N-Dibutyl-tryptamine, N,N-Diethyl-tryptamine, N,N-Diisopropyl-tryptamine, 5-Methyoxy-alpha-methyl-tryptamine, N,N-Dimethyl-tryptamine, 2,alpha-Dimethyl-tryptamine, alpha,N-Dimethyl-tryptamine, N,N-Dipropyl-tryptamine, N-Ethyl-N-isopropyl-tryptamine, alpha-Ethyl-tryptamine, 6,N,N-Triethyl-NL, 3,4-Dihydro-7-methoxy-1-methyl-C, 7-Methyoxy-1-methyl-C, N,N-Dibutyl-4-hydroxy-tryptamine, N,N-Diethyl-4-hydroxy-tryptamine, N,N-Diisopropyl-4-hydroxy-tryptamine, N,N-Dimethyl-4-hydroxy-tryptamine, N,N-Dimethyl-5-hydroxy-tryptamine, N,N-Dipropyl-4-hydroxy-tryptamine, N-Ethyl-4-hydroxy-N-methyl-tryptamine, 4-Hydroxy-N-isopropyl-N-methyl-tryptamine, 4-Hydroxy-N-methyl-N-propyl-tryptamine, 4-Hydroxy-N,N-tetram ethylene-tryptamine, N,N-Diethyl-L, N-Butyl-N-methyl-tryptamine, N,N-Diisopropyl-4,5-methylenedioxy-tryptamine, N,N-Diisopropyl-5,6-methylenedioxy-tryptamine, N,N-Dimethyl-4,5-methylenedioxy-tryptamine, N,N-Dimethyl-5,6-methylenedioxy-tryptamine, N-Isopropyl-N-methyl-5,6-methylenedioxy-tryptamine, N,N-Diethyl-2-methyl-tryptamine, 2, N, N-Trimethyl-tryptamine, N-Acetyl-5-methoxy-tryptamine, N,N-Diethyl-5-methoxy-tryptamine, N,N-Diisopropyl-5-methoxy-tryptamine, 5-Methoxy-N,N-dimethyl-tryptamine, N-Isopropyl-4-methoxy-N-methyl-tryptamine, N-Isopropyl-5-methoxy-N-methyl-tryptamine, 5,6-Dimethoxy-N-isopropyl-N-methyl-tryptamine, 5-Methoxy-N-methyl-tryptamine, 5-Methoxy-N,N-tetramethylene-tryptamine, 6-Methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, 5-Methoxy-2,N,N-trimethyl-tryptamine, N,N-Dimethyl-5-methylthio-tryptamine, N-Isopropyl-N-methyl-tryptamine, alpha-Methyl-tryptamine, N-Ethyl-tryptamine, N-Methyl-tryptamine, 6-Propyl-N L, N,N-Tetramethylene-tryptamine, Tryptamine, 7-Methoxy-1-methyl-1, 2,3,4-tetrahydroisoquinoline, and alpha, N-Dimethyl-5-methoxy-tryptaminedeuterated analogue.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the psychedelic is psilocybin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the psychedelic is 1-acetyl LSD or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the psychedelic is O-acetyl psilocin, or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1-13, wherein the serotonin receptor modulator is a serotonin receptor antagonist.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1-13, wherein the serotonin receptor modulator is a serotonin receptor inverse agonist.

### Claim 16 (depends on 14, 15)

The composition of any one of claims 14-15, wherein the serotonin receptor is 5-HT2A receptor.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The composition of any one of claims 1-16, wherein the serotonin receptor modulator is selected from the group consisting of ketanserin, volinanserin (MDL-100907), eplivanserin (SR-46349), pimavanserin (ACP-103), glemanserin (MDL-11939), ritanserin, flibanserin, nelotanserin, blonanserin, mianserin, mirtazapine, roluperiodone (CYR-101, MIN-101), quetiapine, olanzapine, altanserin, acepromazine, nefazodone, risperidone, pruvanserin, AC-90179, AC-279, adatanserin, fananserin, HY10275, benanserin, butanserin, manserin, iferanserin, lidanserin, pelanserin, seganserin, tropanserin, lorcaserin, ICI-169369, methiothepin, methysergide, trazodone, cinitapride, cyproheptadine, brexpiprazole, cariprazine, agomelatine, setoperone, 1-(1-Naphthyl)piperazine, LY-367265, pirenperone, metergoline, deramciclane, amperozide, AMDA, cinanserin, LY-86057, GSK-215083, cyamemazine, mesulergine, BF-1, LY-215840, sergolexole, spiramide, LY-53857, amesergide, LY-108742, pipamperone, LY-314228, 5-I-R91150, 5-MeO-NBpBrT, 9-Aminomethyl-9,10-dihydroanthracene, niaprazine, SB-215505, SB-204741, SB-206553, SB-242084, LY-272015, SB-243213, SB-200646, and RS-102221, or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, prodrug, or combinations thereof.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The composition of any one of claims 1-17, wherein the serotonin receptor modulator is ketanserin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The composition of any one of claims 1-17, wherein the serotonin receptor modulator is pimavanserin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1-19, wherein the serotonin receptor modulator is released at most about 2.5 hours prior to the release of the psychedelic.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1-19, wherein the serotonin receptor modulator is released at most about 2 hours prior to the release of the psychedelic.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1-19, wherein the serotonin receptor modulator is released at most about 1.5 hours prior to the release of the psychedelic.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1-19, wherein the serotonin receptor modulator is released at most about 1 hour prior to the release of the psychedelic.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1-19, wherein the serotonin receptor modulator is released at about 1 hour prior to the release of the psychedelic.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1-19, wherein the serotonin receptor modulator is released at least about 0.5 hours prior to the release of the psychedelic.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1-19, wherein the serotonin receptor modulator is released at least about 1 hour prior to the release of the psychedelic.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the psychedelic is provided at a dose of about 100 milligrams (mg) to about 1 gram (g).

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the psychedelic is provided at a dose of about 100 mg to about 800 mg.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the psychedelic is provided at a dose of about 100 mg to about 500 mg.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the psychedelic is provided at a dose of about 10 mg to about 400 mg.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the psychedelic is provided at a dose of about 20 mg to about 200 mg.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the psychedelic is provided at a dose of about 10 mg to about 100 mg.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the psychedelic is provided at a dose of about 10 micrograms (μg) to about 400 μg.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the psychedelic is provided at a dose of about 20 μgμg to about 200 μg.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the psychedelic is provided at a dose of about 10 μg μg to about 100 μg μg.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The composition of any one of claims 1-35, wherein the serotonin receptor modulator is provided at a dose of about 10 mg to about 350 mg.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The composition of any one of claims 1-35, wherein the serotonin receptor modulator is provided at a dose of about 20 mg to about 200 mg.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The composition of any one of claims 1-35, wherein the serotonin receptor modulator is provided at a dose of about 10 mg to about 100 mg.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The composition of any one of claims 1-38, wherein the psychedelic is provided at a dose of about 10 mg to about 100 mg and the serotonin receptor modulator is provided at a dose of about 10 mg to about 100 mg.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The composition of any one of claims 1-39, wherein the psychedelic is psilocybin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof and the serotonin receptor modulator is ketanserin or a pharmaceutically acceptable salt thereof.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The composition of any one of claims 1-40, wherein the psychedelic is psilocybin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof and provided at a dose of about 10 mg to about 100 mg; and the serotonin receptor modulator is ketanserin or a pharmaceutically acceptable salt thereof provided at a dose of about 10 mg to about 100 mg.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The composition of any one of claims 1-41, wherein the composition is in a form of a single pill, single ampoule, or single unit dosage form.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The composition of any one of claims 1-39, wherein the composition is in a single unit dosage form.

### Claim 44

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a composition comprising:
a) a psychedelic;
b) a serotonin receptor modulator; and
c) an excipient,
wherein the serotonin receptor modulator is released at most about 3 hours prior to the release of the psychedelic.

### Claim 45 (depends on 44)

The method of claim 44, wherein the disease or disorder is depression or a disease or disorder related to depression.

### Claim 46 (depends on 44)

The method of claim 44, wherein the depression is major depressive disorder, persistent depressive disorder, bipolar disorder, treatment resistant depression (TRD), postpartum depression, premenstrual dysphoric disorder, or seasonal affective disorder.

### Claim 47 (depends on 44)

The method of claim 44, wherein the disease or disorder related to depression is anxiety.

### Claim 48 (depends on 44, 45, 46, 47)

The method of any one of claims 44-47, wherein the psychedelic is an agonist for a serotonin receptor.

### Claim 49 (depends on 48)

The method of claim 48, wherein the serotonin receptor is serotonin receptor 1B, serotonin receptor 4, serotonin receptor 6, or serotonin receptor 7.

### Claim 50 (depends on 44, 45, 46, 47)

The method of any one of claims 44-47, wherein the psychedelic is selected from psilocybin, psilocin, baeocystin, norbaeocystin, lisurgide, LSD, dimethyltryptamine, carboxamindotryptamine, ibogaine, tabernanthalog, 3,4-methylenedioxy-methamphetamine (MDMA), 1-acetyl LSD, O-acetyl psilocin, mescaline (3,4,5-trimethoxy phenethylamine), proscaline (2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine), metaescaline (2-(3-ethoxy-4,5-dimethoxyphenyl)ethanamine), allylescaline (4-Allyloxy-3,5-dimethyloxy phenylethylamine), methallylescaline (4-Methallyloxy-3,5 dimethoxyphenethylamine), and asymbescaline (3,4-Diethoxy-5-methoxyphenethylamine), or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, prodrug, or combinations thereof.

### Claim 51 (depends on 44, 45, 46, 47)

The method of any one of claims 44-47, wherein the psychedelic is LSD or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 52 (depends on 51)

The method of claim 51, wherein the LSD derivative is 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, LSZ, LSM-775, or 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine.

### Claim 53 (depends on 44, 45, 46, 47)

The method of any one of claims 44-47, wherein the psychedelic is mescaline or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 54 (depends on 53)

The method of claim 53, wherein the mescaline derivative is mescaline-NBOMe, proscaline (2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine), or metaescaline (2-(3-ethoxy-4,5-dimethoxyphenyl)ethanamine).

### Claim 55 (depends on 44, 45, 46, 47)

The method of any one of claims 44-47, wherein the psychedelic is a phenethylamine or a tryptamine, or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 56 (depends on 55)

The method of claim 55, wherein the phenethylamine or the tryptamineis selected from 25I-NBOH, N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-iodo-phenethylamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-chloro-phenethylamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-bromo-phenethylamine, 4-Allyloxy-3,5-dimethyloxyphenylethylamine, N-(2-fluorobenzyl)-2,5-dimethoxy-4-iodo-phenethylamine, 2,5-dimethoxy-4-tert-butylthio-phenethylamine, 2,5-dimethoxy-4-propylthio-phenethylamine, 2,5-dimethoxy-4-propylphenethylamine, 2,5-dimethoxy-4-nitrophenethylamine, 2,5-dimethoxy-4-nitroamphetamine, 2,5-dimethoxy-4-methylphenethylamine, 2,5-dimethoxy-4-methylamphetamine, 2,5-dimethoxy-4-isopropylthio-phenethylamine, 2,5-dimethoxy-4-iodophenethylamine, 2,5-dimethoxy-4-iodoamphetamine, 2,5-dimethoxy-4-fluorophenethylamine, 2,5-dimethoxy-4-ethylthio-phenethylamine, 2,5-dimethoxy-4-ethylphenethylamine, 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine, 2,5-dimethoxy-4-chlorophenethylamine, 2,5-dimethoxy-4-chloroamphetamine, 2,5-dimethoxy-4-bromophenethylamine, 2,5-dimethoxy-4-bromoamphetamine, 2,5-dimethoxy-4-bromo-ß-ketophenethylamine, 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine, 2-(4-propyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-methyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-fluoro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 4-AcO-MET, 4-ACO-MALT, 4-AcO-DALT, Aeruginascin, N,N,N-trimethyl-4-phosphoryloxytryptamine, 4-Hydroxy-N,N,N-trimethyltryptamine, 5-meo-DMT, Ibogaine, [3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, 4-hydroxy-N,N-dimethyl-tryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N,N-trimethyltryptamine, 6-Allyl-N,N-diethyl-NL, N,N-Dibutyl-tryptamine, N,N-Diethyl-tryptamine, N,N-Diisopropyl-tryptamine, 5-Methyoxy-alpha-methyl-tryptamine, N,N-Dimethyl-tryptamine, 2,alpha-Dimethyl-tryptamine, alpha,N-Dimethyl-tryptamine, N,N-Dipropyl-tryptamine, N-Ethyl-N-isopropyl-tryptamine, alpha-Ethyl-tryptamine, 6,N,N-Triethyl-NL, 3,4-Dihydro-7-methoxy-1-methyl-C, 7-Methyoxy-1-methyl-C, N,N-Dibutyl-4-hydroxy-tryptamine, N,N-Diethyl-4-hydroxy-tryptamine, N,N-Diisopropyl-4-hydroxy-tryptamine, N,N-Dimethyl-4-hydroxy-tryptamine, N,N-Dimethyl-5-hydroxy-tryptamine, N, N-Dipropyl-4-hydroxy-tryptamine, N-Ethyl-4-hydroxy-N-methyl-tryptamine, 4-Hydroxy-N-isopropyl-N-methyl-tryptamine, 4-Hydroxy-N-methyl-N-propyl-tryptamine, 4-Hydroxy-N,N-tetramethylene-tryptamine, N,N-Diethyl-L, N-Butyl-N-methyl-tryptamine, N,N-Diisopropyl-4,5-methylenedioxy-tryptamine, N,N-Diisopropyl-5,6-methylenedioxy-T, N,N-Dimethyl-4,5-methylenedioxy-tryptamine, N,N-Dimethyl-5,6-methylenedioxy-tryptamine, N-Isopropyl-N-methyl-5,6-methylenedioxy-tryptamine, N,N-Diethyl-2-methyl-tryptamine, 2,N,N-Trimethyl-tryptamine, N-Acetyl-5-methoxy-tryptamine, N,N-Diethyl-5-methoxy-tryptamine, N,N-Diisopropyl-5-methoxy-tryptamine, 5-Methoxy-N, N-dimethyl-tryptamine, N-Isopropyl-4-methoxy-N-methyl-tryptamine, N-Iso-propyl-5-methoxy-N-methyl-tryptamine, 5,6-Dimethoxy-N-isopropyl-N-methyl-tryptamine, 5-Methoxy-N-methyl-tryptamine, 5-Methoxy-N,N-tetramethylene-tryptamine, 6-Methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, 5-Methoxy-2,N,N-trimethyl-tryptamine, N,N-Dimethyl-5-methylthio-tryptamine, N-Isopropyl-N-methyl-tryptamine, alpha-Methyl-tryptamine, N-Ethyl-tryptamine, N-Methyl-tryptamine, 6-Propyl-N L, N,N-Tetramethylene-tryptamine, Tryptamine, 7-Methoxy-1-methyl-1,2,3,4-tetrahydro-C, and alpha, N-Dimethyl-5-methoxy-T.

### Claim 57 (depends on 44, 45, 46, 47)

The method of any one of claims 44-47, wherein the psychedelic is psilocybin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 58 (depends on 44, 45, 46, 47)

The method of any one of claims 44-47, wherein the psychedelic is 1-acetyl LSD or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 59 (depends on 44, 45, 46, 47)

The method of any one of claims 44-47, wherein the psychedelic is O-acetyl psilocin, or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 60 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 44-59, wherein the serotonin receptor modulator is a serotonin receptor antagonist.

### Claim 61 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 44-59, wherein the serotonin receptor modulator is a serotonin receptor inverse agonist.

### Claim 62 (depends on 60, 61)

The method of any one of claims 60-61, wherein the serotonin receptor is 5-HT2A receptor.

### Claim 63 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 44-59, wherein the serotonin receptor modulator is selected from ketanserin, volinanserin (MDL-100907), eplivanserin (SR-46349), pimavanserin (ACP-103), glemanserin (MDL-11939), ritanserin, flibanserin, nelotanserin, blonanserin, mianserin, mirtazapine, roluperiodone (CYR-101, MIN-101), quetiapine, olanzapine, altanserin, acepromazine, nefazodone, risperidone, pruvanserin, AC-90179, AC-279, adatanserin, fananserin, HY10275, benanserin, butanserin, manserin, iferanserin, lidanserin, pelanserin, seganserin, tropanserin, lorcaserin, ICI-169369, methiothepin, methysergide, trazodone, cinitapride, cyproheptadine, brexpiprazole, cariprazine, agomelatine, setoperone, 1-(1-Naphthyl)piperazine, LY-367265, pirenperone, metergoline, deramciclane, amperozide, AMDA, cinanserin, LY-86057, GSK-215083, cyamemazine, mesulergine, BF-1, LY-215840, sergolexole, spiramide, LY-53857, amesergide, LY-108742, pipamperone, LY-314228, 5-I-R91150, 5-MeO-NBpBrT, 9-Aminomethyl-9,10-dihydroanthracene, niaprazine, SB-215505, SB-204741, SB-206553, SB-242084, LY-272015, SB-243213, SB-200646, and RS-102221, or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, prodrug, or combinations thereof.

### Claim 64 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 44-59, wherein the serotonin receptor modulator is ketanserin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 65 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 44-59, wherein the serotonin receptor modulator is pimavanserin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 66 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 44-59, wherein the serotonin receptor modulator is eplivanserin (SR-46,349) or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.

### Claim 67 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 44-66, the serotonin receptor modulator is released at most about 3 hours prior to the release of the psychedelic.

### Claim 68 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 44-66, the serotonin receptor modulator is released at most about 2.5 hours prior to the release of the psychedelic.

### Claim 69 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 44-66, wherein the serotonin receptor modulator is released at most about 2 hours prior to the release of the psychedelic.

### Claim 70 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 44-66, wherein the serotonin receptor modulator is released at most about 1.5 hours prior to the release of the psychedelic.

### Claim 71 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 44-66, wherein the serotonin receptor modulator is released at most about 1 hour prior to the release of the psychedelic.

### Claim 72 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 44-66, wherein the serotonin receptor modulator is released at about 1 hour prior to the release of the psychedelic.

### Claim 73 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 44-66, the serotonin receptor modulator is released at least about 0.5 hours prior to the release of the psychedelic.

### Claim 74 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 44-66, the serotonin receptor modulator is released at least about 1 hour prior to the release of the psychedelic.

### Claim 75 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 44-74, wherein the psychedelic is provided at a dose of about 100 milligrams (mg) to about 1 gram (g).

### Claim 76 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 44-74, wherein the psychedelic is provided at a dose of about 100 mg to about 800 mg.

### Claim 77 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 44-74, wherein the psychedelic is provided at a dose of about 100 mg to about 500 mg.

### Claim 78 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 44-74, wherein the psychedelic is provided at a dose of about 10 mg to about 400 mg.

### Claim 79 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 44-74, wherein the psychedelic is provided at a dose of about 20 mg to about 200 mg.

### Claim 80 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 44-74, wherein the psychedelic is provided at a dose of about 10 mg to about 100 mg.

### Claim 81 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 44-74, wherein the psychedelic is provided at a dose of about 10 micrograms (ug) to about 400 μg.

### Claim 82 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 44-74, wherein the psychedelic is provided at a dose of about 20 μg to about 200 μg.

### Claim 83 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 44-74, wherein the psychedelic is provided at a dose of about 10 μg to about 100 μg.

### Claim 84 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 44-83, wherein the serotonin receptor modulator is provided at a dose of about 10 mg to about 350 mg.

### Claim 85 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 44-83, wherein the serotonin receptor modulator is provided at a dose of about 20 mg to about 200 mg.

### Claim 86 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 44-83, wherein the serotonin receptor modulator is provided at a dose of about 10 mg to about 100 mg.

### Claim 87 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The method of any one of claims 44-86, wherein the psychedelic is provided at a dose of about 10 mg to about 100 mg and the serotonin receptor modulator is provided at a dose of about 10 mg to about 100 mg.

### Claim 88 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The method of any one of claims 44-86, wherein the psychedelic is psilocybin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof and the serotonin receptor modulator is ketanserin or a pharmaceutically acceptable salt thereof.

### Claim 89 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The method of any one of claims 44-86, wherein the psychedelic is psilocybin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof and provided at a dose of about 10 mg to about 100 mg; and the serotonin receptor modulator is ketanserin or a pharmaceutically acceptable salt thereof provided at a dose of about 10 mg to about 100 mg

### Claim 90 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 44-89, wherein the composition is in a form of a single pill, single ampoule, or single unit dosage form.

### Claim 91 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 44-89, wherein the composition is in a single unit dosage form.

### Claim 92

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a psychedelic and a serotonin receptor modulator, wherein the serotonin receptor is administered prior to the administration of the psychedelic, and wherein the serotonin receptor modulator is administered at most about 3 hours prior to the administration of the psychedelic.

### Claim 93

A method of treating a disease or disorder in a subject in need thereof, the method comprising (i) administering to the subject a serotonin receptor modulator to pretreat the subject, and (ii) administering to the subject a psychedelic, and wherein the serotonin receptor modulator is administered at most about 3 hours prior to the administration of the psychedelic.

### Claim 94

A method of reducing the adverse effects of a psychedelic in the treatment of a disease or disorder in a subject in need thereof, the method comprising (i) administering to the subject a serotonin receptor modulator to pretreat the subject, and (ii) administering to the subject a psychedelic, and wherein the serotonin receptor modulator is administered at most about 3 hours prior to the administration of the psychedelic.

### Claim 95 (depends on 92, 93, 94)

The method of any one of claims 92-94, wherein the disease or disorder is depression or a disease or disorder related to depression.
